Forecasts by Molecule Type (Small Molecule, Large Molecule), by Type (Monoclonal Antibodies (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Peptide Antibiotics, Others), by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), by Container Type (Bottles, Ampoules, Vials, Pre-filled Syringes, Bags), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
The Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Rising Demand for Outsourcing Drug Manufacturing by Pharmaceutical Companies to Boost Market Growth Over the last few decades, contract manufacturing organisations (CMOs) have evolved as a viable alternative to pharmaceutical businesses’ in-house research and production departments. Contract manufacturing organisations (CMOs) are proven to be a successful business model as they become more integrated into pharmaceutical firms’ value chains. Despite the fact that the sector as a whole is expanding, many CMOs are encountering new obstacles. As a result of growing expenses, constantly improving technology, and a surge in mergers and acquisitions, competition in this sector has intensified. As a result of these considerations, organisations must decide what actions they might take to defend or improve their position.
Manufacturing costs are much lower in the Asia-Pacific area than in North America and Europe, and favourable laws are fuelling the rise of the CMO business. Despite the fact that API manufacturing services have mostly shifted to China and India, the United States remains the major site for pharmaceutical development outsourcing. Several reasons contribute to this predicament, including the abundance of funding and the concentration of pharmaceutical research hubs in universities. Pharmaceutical development in poor countries is also unfavourable owing to quality difficulties, logistical constraints, and legal challenges.
Market Growth is Hindered by Growing Competition from Small Manufacturers The market’s discontinuance is considered in the perspective of the whole evaluation process for product lifespan and market viability. Drug discontinuation is defined as authorised products that are removed from the market or withdrawn for reasons other than safety or efficacy and are never again discontinued, marketed, exported, or used in the military. The possibility for a pharmaceutical corporation to pull a medicine from the market can have serious effects, including financial losses, loss of goodwill, and disrupted therapeutic research.
The consumer product literature contains well-developed dominating pricing methods, particularly skimming and penetration pricing. Pharmaceutical items use the same market-dynamic pricing mechanisms as other products. According to the current market study, the primary factor determining a product’s pricing is a larger therapeutic benefit. The greater the clinical benefit over previously accessible medications on the market, the higher the initial price of the product. If the sterile injectables medication product’s life cycle was not extended, this incident might result in significant losses for the corporation and, finally, product termination.
What Questions Should You Ask before Buying a Market Research Report? • How is the CMO of Sterile Injectable Drugs market evolving? • What is driving and restraining the CMO of Sterile Injectable Drugs market? • How will each CMO of Sterile Injectable Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032? • How will the market shares for each CMO of Sterile Injectable Drugs submarket develop from 2022 to 2032? • What will be the main driver for the overall market from 2022 to 2032? • Will leading CMO of Sterile Injectable Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032? • Who are the leading players and what are their prospects over the forecast period? • What are the CMO of Sterile Injectable Drugs projects for these leading companies? • How will the industry evolve during the period between 2022 and 2032? What are the implications of CMO of Sterile Injectable Drugs projects taking place now and over the next 10 years? • Is there a greater need for product commercialisation to further scale the CMO of Sterile Injectable Drugs market? • Where is the CMO of Sterile Injectable Drugs market heading and how can you ensure you are at the forefront of the market? • What are the best investment options for new product and service lines? • What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the CMO of Sterile Injectable Drugs market today, and over the next 10 years: • Our 357-page report provides 116 tables and 175 charts/graphs exclusively to you. • The report highlights key lucrative areas in the industry so you can target them – NOW. • It contains in-depth analysis of global, regional and national sales and growth. • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the CMO of Sterile Injectable Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares. • You will find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CMO of Sterile Injectable Drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:
North America • U.S. • Canada
Europe • Germany • UK • France • Spain • Italy • Russia • Rest of Europe
Asia Pacific • China • Japan • India • Australia • South Korea • Rest of Asia Pacific
Latin America • Brazil • Mexico • Rest of Latin America
The report also includes profiles and for some of the leading companies in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth • Adare Pharma Solutions • Aenova Group • Almac Group • Avara Pharmaceutical Services, Inc. • Baxter International Inc. • Boehringer Ingelheim International GmbH • Catalent, Inc. • CordenPharma • Eli Lilly and Company • Evonik Industries AG • F. Hoffmann-La Roche Ltd • FAMAR Health Care Services • Fresenius Kabi Ag • Grifols SA • Hikma Pharmaceuticals PLC • Jubilant Pharmova Limited • Lonza • Nexus Pharmaceuticals, Inc. • Patheon, Inc. (Thermo Fischer) • Pfizer CentreOne • Recipharm AB • Siegfried Holding AG
Overall world revenue for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 in terms of value the market will surpass US$22,300.0 million in 2023, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 report help you? In summary, our 370+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 Market, with forecasts for molecule type, type, application, container type, and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 18 key national markets – See forecasts for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, LA, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Buy our report today Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032: Forecasts by Molecule Type (Small Molecule, Large Molecule), by Type (Monoclonal Antibodies (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Peptide Antibiotics, Others), by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), by Container Type (Bottles, Ampoules, Vials, Pre-filled Syringes, Bags), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview 1.1 Objectives of the Study 1.2 Introduction to CMO of Sterile Injectable Drugs Market 1.3 What This Report Delivers 1.4 Why You Should Read This Report 1.5 Key Questions Answered by This Analytical Report Include: 1.6 Who is This Report For? 1.7 Methodology 1.7.1 Market Definitions 1.7.2 Market Evaluation & Forecasting Methodology 1.7.3 Data Validation 1.7.3.1 Primary Research 1.7.3.2 Secondary Research 1.8 Frequently Asked Questions (FAQs) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2 Executive Summary
3 Market Overview 3.1 Key Findings 3.2 Market Dynamics 3.2.1 Market Driving Factors 3.2.1.1 Growing Focus on Development to Treat Cancer 3.2.1.2 Rising Prevalence of Chronic Diseases 3.2.1.3 Rapid FDA Approvals of Sterile Injectable Drugs to Fuel Market Growth 3.2.1.4 As Manufacturers Invest in New Manufacturing Facilities, The Demand for Sterile Injectables is Expected to Rise 3.2.1.5 Increasing Demand for Biologicals is Expected to Drive the Demand 3.2.2 Market Restraining Factors 3.2.2.1 Growing Competition from Small Manufacturers 3.2.2.2 High Operational Costs 3.2.2.3 Inadequate Healthcare Infrastructure Across Developing Economies Challenging Market Growth 3.2.3 Market Opportunities 3.2.3.1 Prefilled Syringes to Offer Lucrative Growth Prospects 3.2.3.2 Growing Investments 3.2.3.3 Expanding Clinical Trial Opportunities in the Asia Pacific Region 3.2.4 Market Challenges 3.2.4.1 Disruption of Clinical Trials Due to Pandemic Breakout 3.3 COVID-19 Impact Analysis 3.4 Porter’s Five Forces Analysis 3.4.1 Supplier Power 3.4.2 Buyer Power 3.4.3 Competitive Rivalry 3.4.4 Threat from Substitutes 3.4.5 Threat of New Entrants 3.5 PEST Analysis 3.5.1 Political Factors Impacting CMO of Sterile Injectable Drugs Market 3.5.2 Economic Factors Impacting CMO of Sterile Injectable Drugs Market 3.5.3 Social Factors Impacting CMO of Sterile Injectable Drugs Market 3.5.4 Technological Factors Impacting CMO of Sterile Injectable Drugs Market
4 CMO of Sterile Injectable Drugs Market Analysis by Molecule Type 4.1 Key Findings 4.2 Molecule Type Segment: Market Attractiveness Index 4.3 CMO of Sterile Injectable Drugs Market Share by Molecule Type, 2022 & 2032 4.4 Small Molecule 4.5 Large Molecule 4.6 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
5 CMO of Sterile Injectable Drugs Market Analysis by Type 5.1 Key Findings 5.2 Type Segment: Market Attractiveness Index 5.3 CMO of Sterile Injectable Drugs Market Share by Type, 2022 & 2032 5.4 Monoclonal Antibodies (mAbs) 5.5 Cytokines 5.6 Insulin 5.7 Peptide Hormones 5.8 Vaccines 5.9 Immunoglobulins 5.10 Blood Factor 5.11 Peptide Antibiotics 5.12 Others 5.13 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
6 CMO of Sterile Injectable Drugs Market Analysis by Application 6.1 Key Findings 6.2 Application Segment: Market Attractiveness Index 6.3 CMO of Sterile Injectable Drugs Market Share by Application, 2022 & 2032 6.4 Cancer 6.5 Diabetes 6.6 Cardiovascular Diseases 6.7 CNS 6.8 Infectious 6.9 Others 6.10 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
7 CMO of Sterile Injectable Drugs Market Analysis by Container Type 7.1 Key Findings 7.2 Container Type Segment: Market Attractiveness Index 7.3 CMO of Sterile Injectable Drugs Market Share by Container Type, 2022 & 2032 7.4 Bottles 7.5 Ampoules 7.6 Vials 7.7 Prefilled Syringes 7.8 Bags 7.9 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
8 CMO of Sterile Injectable Drugs Market Analysis by Route of Administration 8.1 Key Findings 8.2 Route of Administration Segment: Market Attractiveness Index 8.3 CMO of Sterile Injectable Drugs Market Share by Route of Administration, 2022 & 2032 8.4 Subcutaneous 8.5 Intravenous 8.6 Intramuscular 8.7 Others 8.8 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
9 CMO of Sterile Injectable Drugs Market Analysis by Service 9.1 Key Findings 9.2 Service Segment: Market Attractiveness Index 9.3 CMO of Sterile Injectable Drugs Market Share by Service, 2022 & 2032 9.4 Bioanalytical Testing 9.5 Method Development & Validation 9.6 Stability Testing 9.7 Others 9.8 CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
10 CMO of Sterile Injectable Drugs Market Analysis by Region 10.1 Key Findings 10.2 Regional Market Size Estimation and Forecast
11 North America CMO of Sterile Injectable Drugs Market Analysis 11.1 Key Findings 11.2 North America CMO of Sterile Injectable Drugs Market Attractiveness Index 11.3 North America CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn) 11.4 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country 11.5 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type 11.6 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type 11.7 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application 11.8 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type 11.9 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration 11.10 North America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service 11.11 U.S. 11.12 Canada
12 Europe CMO of Sterile Injectable Drugs Market Analysis 12.1 Key Findings 12.2 Europe CMO of Sterile Injectable Drugs Market Attractiveness Index 12.3 Europe CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn) 12.4 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country 12.5 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type 12.6 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type 12.7 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application 12.8 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type 12.9 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration 12.10 Europe CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service 12.11 Germany 12.12 U.K. 12.13 France 12.14 Italy 12.15 Spain 12.16 Russia 12.17 Rest of Europe
13 Asia Pacific CMO of Sterile Injectable Drugs Market Analysis 13.1 Key Findings 13.2 Asia Pacific CMO of Sterile Injectable Drugs Market Attractiveness Index 13.3 Asia Pacific CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn) 13.4 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country 13.5 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type 13.6 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type 13.7 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application 13.8 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type 13.9 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration 13.10 Asia Pacific CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service 13.11 China 13.12 Japan 13.13 India 13.14 Australia 13.15 South-East Asia 13.16 Rest of Asia Pacific
14 Latin America CMO of Sterile Injectable Drugs Market Analysis 14.1 Key Findings 14.2 Latin America CMO of Sterile Injectable Drugs Market Attractiveness Index 14.3 Latin America CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn) 14.4 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country 14.5 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type 14.6 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type 14.7 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application 14.8 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type 14.9 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration 14.10 Latin America CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service 14.11 Brazil 14.12 Mexico 14.13 Rest of Latin America
15 Middle East & Africa CMO of Sterile Injectable Drugs Market Analysis 15.1 Key Findings 15.2 Middle East & Africa CMO of Sterile Injectable Drugs Market Attractiveness Index 15.3 Middle East & Africa CMO of Sterile Injectable Drugs Market by Country, 2022, 2027 & 2032 (US$ mn) 15.4 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Country 15.5 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type 15.6 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Type 15.7 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Application 15.8 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type 15.9 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration 15.10 Middle East & Africa CMO of Sterile Injectable Drugs Market Size Estimation and Forecast by Service 15.11 GCC 15.12 South Africa 15.13 Rest of Middle East & Africa
16 Competitive Landscape 16.1 Company Share Analysis 16.2 Key Business Strategy Analysis
17 Company Profiles 17.1 Aenova Group 17.1.1 Company Snapshot 17.1.2 Company Overview 17.1.3 Product Benchmarking 17.1.4 Strategic Outlook 17.2 Almac Group 17.2.1 Company Snapshot 17.2.2 Company Overview 17.2.3 Product Benchmarking 17.2.4 Strategic Outlook 17.3 Baxter International Inc. 17.3.1 Company Snapshot 17.3.2 Company Overview 17.3.3 Financial Analysis 17.3.3.1 Net Revenue, 2017-2021 17.3.3.2 Regional Revenue/Market Shares, 2020 17.3.4 Product Benchmarking 17.3.5 Strategic Outlook 17.4 Boehringer Ingelheim International GmbH 17.4.1 Company Snapshot 17.4.2 Company Overview 17.4.3 Financial Analysis 17.4.3.1 Net Revenue, 2017-2021 17.4.3.2 Regional Revenue/Market Shares, 2021 17.4.3.3 Segmental Revenue/Market Shares, 2021 17.4.4 Product Benchmarking 17.5 Catalent, Inc. 17.5.1 Company Snapshot 17.5.2 Company Overview 17.5.3 Financial Analysis 17.5.3.1 Net Revenue, 2017-2021 17.5.3.2 Regional Revenue/Market Shares, 2021 17.5.3.3 Segmental Revenue/Market Shares, 2021 17.5.4 Product Benchmarking 17.5.5 Strategic Outlook 17.6 CordenPharma 17.6.1 Company Snapshot 17.6.2 Company Overview 17.6.3 Product Benchmarking 17.6.4 Strategic Outlook 17.7 Evonik Industries AG 17.7.1 Company Snapshot 17.7.2 Company Overview 17.7.3 Financial Analysis 17.7.3.1 Net Revenue, 2017-2021 17.7.3.2 Regional Revenue/Market Shares, 2021 17.7.3.3 Segmental Revenue/Market Shares, 2021 17.7.4 Product Benchmarking 17.7.5 Strategic Outlook 17.8 FAMAR Health Care Services 17.8.1 Company Snapshot 17.8.2 Company Overview 17.8.3 Product Benchmarking 17.8.4 Strategic Outlook 17.9 Fresenius Kabi Ag 17.9.1 Company Snapshot 17.9.2 Company Overview 17.9.3 Financial Analysis 17.9.3.1 Net Revenue, 2017-2021 17.9.3.2 Regional Revenue/Market Shares, 2021 17.9.3.3 Segmental Revenue/Market Shares, 2021 17.9.4 Product Benchmarking 17.9.5 Strategic Outlook 17.10 Grifols SA 17.10.1 Company Snapshot 17.10.2 Company Overview 17.10.3 Financial Analysis 17.10.3.1 Net Revenue, 2017-2021 17.10.3.2 Regional Revenue/Market Shares, 2021 17.10.3.3 Segmental Revenue/Market Shares, 2021 17.10.4 Product Benchmarking 17.10.5 Strategic Outlook 17.11 Hikma Pharmaceuticals PLC 17.11.1 Company Snapshot 17.11.2 Company Overview 17.11.3 Financial Analysis 17.11.3.1 Net Revenue, 2017-2021 17.11.3.2 Regional Revenue/Market Shares, 2021 17.11.3.3 Segmental Revenue/Market Shares, 2021 17.11.4 Product Benchmarking 17.11.5 Strategic Outlook 17.12 Jubilant Pharmova Limited 17.12.1 Company Snapshot 17.12.2 Company Overview 17.12.3 Financial Analysis 17.12.3.1 Net Revenue, 2017-2021 17.12.3.2 Regional Revenue/Market Shares, 2021 17.12.3.3 Segmental Revenue/Market Shares, 2021 17.12.4 Product Benchmarking 17.12.5 Strategic Outlook 17.13 Lonza 17.13.1 Company Snapshot 17.13.2 Company Overview 17.13.3 Financial Analysis 17.13.3.1 Net Revenue, 2017-2021 17.13.3.2 Regional Revenue/Market Shares, 2021 17.13.3.3 Segmental Revenue/Market Shares, 2021 17.13.4 Product Benchmarking 17.13.5 Strategic Outlook 17.14 Patheon, Inc. (Thermo Fischer) 17.14.1 Company Snapshot 17.14.2 Company Overview 17.14.3 Financial Analysis 17.14.3.1 Net Revenue, 2017-2021 17.14.3.2 Regional Revenue/Market Shares, 2021 17.14.3.3 Segmental Revenue/Market Shares, 2021 17.14.4 Product Benchmarking 17.14.5 Strategic Outlook 17.15 Pfizer CentreOne 17.15.1 Company Snapshot 17.15.2 Company Overview 17.15.3 Financial Analysis 17.15.3.1 Net Revenue, 2017-2021 17.15.3.2 Regional Revenue/Market Shares, 2021 17.15.3.3 Segmental Revenue/Market Shares, 2021 17.15.4 Product Benchmarking 17.15.5 Strategic Outlook 17.16 Recipharm AB 17.16.1 Company Snapshot 17.16.2 Company Overview 17.16.3 Product Benchmarking 17.16.4 Strategic Outlook 17.17 Siegfried Holding AG 17.17.1 Company Snapshot 17.17.2 Company Overview 17.17.3 Financial Analysis 17.17.3.1 Net Revenue, 2017-2021 17.17.3.2 Regional Revenue/Market Shares, 2021 17.17.3.3 Segmental Revenue/Market Shares, 2021 17.17.4 Product Benchmarking 17.17.5 Strategic Outlook 17.18 Nexus Pharmaceuticals, Inc. 17.18.1 Company Snapshot 17.18.2 Company Overview 17.18.3 Product Benchmarking 17.18.4 Strategic Outlook 17.19 Avara Pharmaceutical Services, Inc. 17.19.1 Company Snapshot 17.19.2 Company Overview 17.19.3 Product Benchmarking 17.20 Eli Lilly and Company 17.20.1 Company Snapshot 17.20.2 Company Overview 17.20.3 Financial Analysis 17.20.3.1 Net Revenue, 2017-2021 17.20.3.2 Regional Revenue/Market Shares, 2021 17.20.4 Product Benchmarking 17.20.5 Strategic Outlook 17.21 Adare Pharma Solutions 17.21.1 Company Snapshot 17.21.2 Company Overview 17.21.3 Product Benchmarking 17.21.4 Strategic Outlook
18 Conclusion and Recommendations 18.1 Concluding Remarks from Visiongain 18.2 Recommendations for Market Players
List of Tables Table 1 CMO of Sterile Injectable Drugs Market Snapshot, 2022 & 2032 (US$ million, CAGR %) Table 2 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “V” Shaped Recovery Scenario Table 3 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “U” Shaped Recovery Scenario Table 4 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “W” Shaped Recovery Scenario Table 5 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “L” Shaped Recovery Scenario Table 6 CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 7 CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 8 CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR%, CAGR %) Table 9 CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 10 CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR%, CAGR %) Table 11 CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR%, CAGR %) Table 12 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)) Table 13 North America CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 14 North America CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 15 North America CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 16 North America CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR%, CAGR%) Table 17 North America CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 18 North America CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR%, CAGR %) Table 19 North America CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR%, CAGR %) Table 20 U.S. CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 21 Canada CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 22 Europe CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 23 Europe CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 24 Europe CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 25 Europe CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR%, CAGR %) Table 26 Europe CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 27 Europe CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR%, CAGR %) Table 28 Europe CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR%, CAGR %) Table 29 Germany CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 30 U.K. CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 31 France CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 32 Italy CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 33 Spain CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 34 Russia CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 35 Rest of Europe CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 36 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 37 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 38 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 39 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR%, CAGR %) Table 40 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 41 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR%, CAGR %) Table 42 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR%, CAGR%) Table 43 China CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 44 Japan CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 45 India CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 46 Australia CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 47 South-East Asia CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 48 Rest of Asia Pacific CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 49 Latin America CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 50 Latin America CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 51 Latin America CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 52 Latin America CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR%, CAGR %) Table 53 Latin America CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 54 Latin America CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR%, CAGR %) Table 55 Latin America CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR%, CAGR %) Table 56 Brazil CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 57 Mexico CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 58 Rest of Latin America CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 59 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %) Table 60 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 61 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %) Table 62 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR%, CAGR %) Table 63 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR%, CAGR%) Table 64 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR%, CAGR %) Table 65 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR%, CAGR %) Table 66 GCC CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 67 South Africa CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR %) Table 68 Rest of Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR%, CAGR%) Table 69 Company Ranking, 2021 Patheon, Inc. (Thermo Fischer) Table 70 Strategic Outlook 2018-2022 Table 71 Aenova Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 72 Aenova Group: Product Benchmarking Table 73 Aenova Group: Strategic Outlook Table 74 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 75 Almac Group: Product Benchmarking Table 76 Almac Group: Strategic Outlook Table 77 Baxter International Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 78 Baxter International Inc.: Product Benchmarking Table 79 Baxter International Inc. : Strategic Outlook Table 80 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 81 Boehringer Ingelheim International GmbH: Product Benchmarking Table 82 Catalent, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 83 Catalent, Inc.: Product Benchmarking Table 84 Catalent, Inc: Strategic Outlook Table 85 CordenPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 86 CordenPharma: Product Benchmarking Table 87 CordenPharma: Strategic Outlook Table 88 Evonik Industries AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 89 Evonik Industries AG: Product Benchmarking Table 90 Evonik Industries AG: Strategic Outlook Table 91 FAMAR Health Care Services: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 92 FAMAR Health Care Services: Product Benchmarking Table 93 FAMAR Health Care Services: Strategic Outlook Table 94 Fresenius Kabi Ag: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 95 Fresenius Kabi Ag: Product Benchmarking Table 96 Fresenius Kabi Ag: Strategic Outlook Table 97 Grifols SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 98 Grifols SA: Product Benchmarking Table 99 Grifols SA: Strategic Outlook Table 100 Hikma Pharmaceuticals PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 101 Hikma Pharmaceuticals PLC: Product Benchmarking Table 102 Hikma Pharmaceuticals PLC: Strategic Outlook Table 103 Jubilant Pharmova Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 104 Jubilant Pharmova Limited: Product Benchmarking Table 105 Jubilant Pharmova Limited: Strategic Outlook Table 106 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 107 Lonza: Product Benchmarking Table 108 Lonza: Strategic Outlook Table 109 Patheon, Inc. (Thermo Fischer): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 110 Patheon, Inc. (Thermo Fischer): Product Benchmarking Table 111 Patheon, Inc. (Thermo Fischer): Strategic Outlook Table 112 Pfizer CentreOne: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 113 Pfizer CentreOne: Product Benchmarking Table 114 Pfizer CentreOne: Strategic Outlook Table 115 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 116 Recipharm AB : Product Benchmarking Table 117 Recipharm AB: Strategic Outlook Table 118 Siegfrid Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 119 Siegfried Holding AG: Product Benchmarking Table 120 Siegfried Holding AG: Strategic Outlook Table 121 Nexus Pharmaceuticals, Inc. Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 122 Nexcus Pharmaceuticals, Inc.: Product Benchmarking Table 123 Nexus Pharmaceuticals, Inc.: Strategic Outlook Table 124 Avara Pharmaceutical Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 125 Avara Pharmaceutical Services, inc.: Product Benchmarking Table 126 Patheon, Inc. (Thermo Fischer): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 127 Eli Lilly and Company: Product Benchmarking Table 128 Eli Lilly and Company : Strategic Outlook Table 129 Adare Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 130 Adare Pharma Solutions: Product Benchmarking Table 131 Adare Pharma Solutions: Strategic Outlook
List of Figures Figure 1 CMO of Sterile Injectable Drugs Market Segmentation Figure 2 CMO of Sterile Injectable Drugs Market Forecast by Region: Market Attractiveness Index Figure 3 CMO of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index Figure 4 CMO of Sterile Injectable Drugs Market by Type: Market Attractiveness Index Figure 5 CMO of Sterile Injectable Drugs Market by Application: Market Attractiveness Index Figure 6 CMO of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index Figure 7 CMO of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index Figure 8 CMO of Sterile Injectable Drugs Market by Service: Market Attractiveness Index Figure 9 CMO of Sterile Injectable Drugs Market: Market Dynamics Figure 10 Pharmaceutical R&D Expenditure in Europe, U.S., Japan & China, 2019 and 2020 Figure 11 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “V” Shaped Recovery Figure 12 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “U” Shaped Recovery Figure 13 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “W” Shaped Recovery Figure 14 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)): “L” Shaped Recovery Figure 15 CMO of Sterile Injectable Drugs Market: Porter’s Five Forces Analysis Figure 16 CMO of Sterile Injectable Drugs Market: PEST Analysis Figure 17 CMO of Sterile Injectable Drugs Market Forecast by Molecule Type 2022, 2027, 2032 (Revenue, CAGR %) Figure 18 CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022, 2032 (%) Figure 19 CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR %) Figure 20 CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022, 2027, 2032 (%) Figure 21 CMO of Sterile Injectable Drugs Market Forecast by Type 2022, 2027, 2032 (Revenue, CAGR %) Figure 22 CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022, 2032 (%) Figure 23 CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 24 CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022, 2027, 2032 (%) Figure 25 CMO of Sterile Injectable Drugs Market Forecast by Application 2022, 2027, 2032 (Revenue, CAGR %) Figure 26 CMO of Sterile Injectable Drugs Market Share Forecast by Application, 2022, 2032 (%) Figure 27 CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR %) Figure 28 CMO of Sterile Injectable Drugs Market Share Forecast by Application, 2022, 2027, 2032 (%) Figure 29 CMO of Sterile Injectable Drugs Market Forecast by Container Type 2022, 2027, 2032 (Revenue, CAGR %) Figure 30 CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022, 2032 (%) Figure 31 CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR %) Figure 32 CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022, 2027, 2032 (%) Figure 33 CMO of Sterile Injectable Drugs Market Forecast by Route of Administration 2022, 2027, 2032 (Revenue, CAGR %) Figure 34 CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022, 2032 (%) Figure 35 CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR %) Figure 36 CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022, 2027, 2032 (%) Figure 37 CMO of Sterile Injectable Drugs Market Forecast by Service 2022, 2027, 2032 (Revenue, CAGR %) Figure 38 CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022, 2032 (%) Figure 39 CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR %) Figure 40 CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022, 2027, 2032 (%) Figure 41 CMO of Sterile Injectable Drugs Market Share Forecast by Region 2022, 2027, 2032(%) Figure 42 CMO of Sterile Injectable Drugs Market by Region, 2022-2032 (US$ mn, AGR (%), CAGR (%)) Figure 43 North America CMO of Sterile Injectable Drugs Market Attractiveness Index Figure 44 North America CMO of Sterile Injectable Drugs Market by Region, 2022, 2027 & 2032 (US$ million) Figure 45 North America CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 46 North America CMO of Sterile Injectable Drugs Market Share Forecast by Country, 2022 & 2032 (%) Figure 47 North America CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR %) Figure 48 North America CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022 & 2032 (%) Figure 49 North America CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 50 North America CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022 & 2032 (%) Figure 51 North America CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR %) Figure 52 North America CMO of Sterile Injectable Drugs Market Share Forecast by Application, 2022 & 2032 (%) Figure 53 North America CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR %) Figure 54 North America CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022 & 2032 (%) Figure 55 North America CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR %) Figure 56 North America CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%) Figure 57 North America CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR %) Figure 58 North America CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022 & 2032 (%) Figure 59 U.S. CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 60 Canada CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 61 Europe CMO of Sterile Injectable Drugs Market Attractiveness Index Figure 62 Europe CMO of Sterile Injectable Drugs Market by Region, 2022, 2027 & 2032 (US$ million) Figure 63 Europe CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 64 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Country, 2022 & 2032 (%) Figure 65 Europe CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR %) Figure 66 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022 & 2032 (%) Figure 67 Europe CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 68 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022 & 2032 (%) Figure 69 Europe CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR %) Figure 70 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Application, 2022 & 2032 (%) Figure 71 Europe CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR %) Figure 72 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022 & 2032 (%) Figure 73 Europe CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR %) Figure 74 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%) Figure 75 Europe CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR %) Figure 76 Europe CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022 & 2032 (%) Figure 77 Germany CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 78 U.K. CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 79 France CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 80 Italy CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 81 Spain CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 82 Russia CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 83 Rest of Europe CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 84 Asia Pacific CMO of Sterile Injectable Drugs Market Attractiveness Index Figure 85 Asia Pacific CMO of Sterile Injectable Drugs Market by Region, 2022, 2027 & 2032 (US$ million) Figure 86 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 87 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Country, 2022 & 2032 (%) Figure 88 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR %) Figure 89 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022 & 2032 (%) Figure 90 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 91 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022 & 2032 (%) Figure 92 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 93 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022 & 2032 (%) Figure 94 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR %) Figure 95 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022 & 2032 (%) Figure 96 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR %) Figure 97 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%) Figure 98 Asia Pacific CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR %) Figure 99 Asia Pacific CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022 & 2032 (%) Figure 100 China CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 101 Japan CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 102 India CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 103 Australia CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 104 South-East Asia CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 105 Rest of Asia Pacific CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 106 Latin America CMO of Sterile Injectable Drugs Market Attractiveness Index Figure 107 Latin America CMO of Sterile Injectable Drugs Market by Region, 2022, 2027 & 2032 (US$ million) Figure 108 Latin America CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 109 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Country, 2022 & 2032 (%) Figure 110 Latin America CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR %) Figure 111 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022 & 2032 (%) Figure 112 Latin America CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 113 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022 & 2032 (%) Figure 114 Latin America CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR %) Figure 115 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Application, 2022 & 2032 (%) Figure 116 Latin America CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR %) Figure 117 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022 & 2032 (%) Figure 118 Latin America CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR %) Figure 119 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%) Figure 120 Latin America CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR %) Figure 121 Latin America CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022 & 2032 (%) Figure 122 Brazil CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 123 Mexico CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 124 Rest of Latin America CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 125 Middle East & Africa CMO of Sterile Injectable Drugs Market Attractiveness Index Figure 126 Middle East & Africa CMO of Sterile Injectable Drugs Market by Region, 2022, 2027 & 2032 (US$ million) Figure 127 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Country, 2022-2032 (US$ million, AGR %) Figure 128 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Country, 2022 & 2032 (%) Figure 129 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Molecule Type, 2022-2032 (US$ million, AGR %) Figure 130 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2022 & 2032 (%) Figure 131 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Type, 2022-2032 (US$ million, AGR %) Figure 132 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Type, 2022 & 2032 (%) Figure 133 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Application, 2022-2032 (US$ million, AGR %) Figure 134 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Application, 2022 & 2032 (%) Figure 135 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Container Type, 2022-2032 (US$ million, AGR %) Figure 136 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Container Type, 2022 & 2032 (%) Figure 137 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Route of Administration, 2022-2032 (US$ million, AGR %) Figure 138 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2022 & 2032 (%) Figure 139 Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast by Service, 2022-2032 (US$ million, AGR %) Figure 140 Middle East & Africa CMO of Sterile Injectable Drugs Market Share Forecast by Service, 2022 & 2032 (%) Figure 141 GCC CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 142 South Africa CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 143 Rest of Middle East & Africa CMO of Sterile Injectable Drugs Market Forecast, 2022-2032 (US$ million, AGR %) Figure 144 Baxter International Inc. : Net Revenue, 2017-2021 (US$ million, AGR %) Figure 145 Baxter International Inc. : Regional Revenue Shares, 2021 Figure 146 Boehringer Ingelheim International GmbH: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 147 Boehringer Ingelheim International GmbH: Regional Revenue Shares, 2021 Figure 148 Boehringer Ingelheim International GmbH : Segmental Revenue Shares, 2021 Figure 149 Catalent, Inc.: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 150 Catalent, Inc.: Regional Revenue Shares, 2021 Figure 151 Catalent, Inc.: Segmental Revenue Shares, 2021 Figure 152 Evonik Industries AG: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 153 Evonik Industries AG : Regional Revenue Shares, 2021 Figure 154 Evonik Industries AG: Segmental Revenue Shares, 2021 Figure 155 Fresenius Kabi Ag: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 156 Fresenius Kabi Ag: Regional Revenue Shares, 2021 Figure 157 Fresenius Kabi Ag: Segmental Revenue Shares, 2021 Figure 158 Grifols SA: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 159 Grifols SA: Regional Revenue Shares, 2021 Figure 160 Grifols SA : Segmental Revenue Shares, 2021 Figure 161 Hikma Pharmaceuticals PLC: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 162 Hikma Pharmaceuticals PLC: Regional Revenue Shares, 2021 Figure 163 Hikma Pharmaceuticals PLC: Segmental Revenue Shares, 2021 Figure 164 Jubilant Pharmova Limited: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 165 Jubilant Pharmova Limited. : Regional Revenue Shares, 2021 Figure 166 Jubilant Pharmova Limited : Segmental Revenue Shares, 2021 Figure 167 Lonza: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 168 Lonza: Regional Revenue Shares, 2021 Figure 169 Lonza: Segmental Revenue Shares, 2021 Figure 170 Patheon, Inc. (Thermo Fischer): Net Revenue, 2017-2021 (US$ million, AGR %) Figure 171 Patheon, Inc. (thermo Fischer): Regional Revenue Shares, 2021 Figure 172 Patheon, Inc. (Thermo Fischer): Segmental Revenue Shares, 2021 Figure 173 Pfizer CentreOne: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 174 Pfizer CentreOne : Regional Revenue Shares, 2021 Figure 175 Pfizer CentreOne : Segmental Revenue Shares, 2021 Figure 176 Siegfried Holding AG: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 177 Siegfried Holding AG: Regional Revenue Shares, 2021 Figure 178 Siegfried Holding AG: Segmental Revenue Shares, 2021 Figure 179 Eli Lilly and Company: Net Revenue, 2017-2021 (US$ million, AGR %) Figure 180 Eli Lilly and Company: Regional Revenue Shares, 2021
List of Companies Profiled in the Report Adare Pharma Solutions Aenova Group Almac Group Avara Pharmaceutical Services, Inc. Baxter International Inc. Boehringer Ingelheim International GmbH Catalent, Inc. CordenPharma Eli Lilly and Company Evonik Industries AG F. Hoffmann-La Roche Ltd FAMAR Health Care Services Fresenius Kabi Ag Grifols SA Hikma Pharmaceuticals PLC Jubilant Pharmova Limited Lonza Nexus Pharmaceuticals, Inc. Patheon, Inc. (Thermo Fischer) Pfizer CentreOne Recipharm AB Siegfried Holding AG
List of Other Companies Mentioned in the Report Acucela Autolus AveXis BioCancell Biomay Biomiga BioReliance Biotec Services International Celladon Cellectis Cellular Biomedicine Group Delphi Genetics Desktop Genetics DNAtrix Elixirgen Scientific Epeius Biotechnologies EUFETS Eurofins Genomics GEG Tech Genable Technologies Immune Application Immune Design ImmunoGenes Inbiomed VIVEbiotech Waisman Biomanufacturing Xpress Biologics
List of Associations Mentioned in the Report Association of British Pharmaceutical Industry (ABPI) Central Drugs Standard Control Organization (CDSCO) Department of Health and Family Welfare Development and Reform Commission (NDRC) European Commission European Medicines Agency (EMA) Food and Drug Administration (US FDA) Indian Drug Manufacturer's Association (IDMA) International Society of Pharmaceutical Engineering (IPSE) Korea Food and Drug Administration (KFDA) Korea Pharmaceutical Manufacturer's Association (KPMA) Medicines and Healthcare Products Regulatory Agency (MHRA) Medicines Manufacturing Industry Partnership (MMIP) Ministry of Health (MOH) Ministry of Health, Labor and Welfare (MHLW) Ministry of Industry and Information Application (MIIT) Pharmaceutical and Medical Devices Agency (PMDA) World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D,...
Complete the form below to download your free sample pages for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Single-Use Bioprocessing Probes & Sensors market was valued US$2,493.8 million in 2022 and is projected to grow at a CAGR of 15.2% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
